Adult-Onset Still's Disease

Our Approach to Treating Adult-Onset Still's Disease

Faced with an unpredictable, multi-organ autoinflammatory disease like AOSD, Haute-Derma follows a strategy of rigorous exclusion and deep, targeted control:

• Rigorous diagnosis of exclusion: a comprehensive workup to fully rule out infection (bacterial, viral), hematologic malignancy and systemic connective tissue disease before AOSD is diagnosed.
• Close monitoring of dynamic biomarkers: serum ferritin and the glycosylated ferritin fraction serve as a running gauge of disease activity, response to treatment and early warning of complications.
• Treatment tailored to the disease course: we identify each patient's pattern (self-limiting monocyclic, relapsing polycyclic, or chronic articular) and choose a suitable maintenance plan that keeps drug toxicity to a minimum.

How We Diagnose Adult-Onset Still's Disease at Haute-Derma

To confirm AOSD, Haute-Derma uses the most sensitive standard available today, the Yamaguchi criteria (at least 5 criteria, including at least 2 major criteria):

Major Criteria

• Spiking high fever (Still's fever pattern): fever above 39°C, typically spiking once or twice a day in the late afternoon or late at night, then returning to normal by morning without strong fever-reducing medication.
• Evanescent salmon-pink rash: a characteristic rash of small salmon-pink macules or papules that are not itchy or only mildly itchy, mainly on the trunk and upper limbs. Its hallmark is that it appears together with the fever spikes and disappears completely when the fever settles.
• Arthritis or joint pain: joint pain or arthritis lasting more than 2 weeks, usually in large and medium joints such as the knees, ankles, wrists and elbows, often symmetrical or migratory.
• Raised white blood cell count: a peripheral white cell count above 10,000/mm³, with neutrophils clearly predominating (over 80%).

Minor Criteria

• Sore throat: a severe, persistent sore throat from the very start of the illness (the throat looks red and inflamed, but cultures are negative).
• Swollen lymph nodes or enlarged liver and spleen: soft, mobile superficial lymph nodes (usually in the neck, armpits or groin) and an enlarged liver and spleen due to reactive expansion of the reticuloendothelial system.
• Abnormal liver function: blood tests show clearly raised liver enzymes (AST, ALT) and LDH without a common viral hepatitis cause.
• Negative antinuclear antibodies (ANA) and rheumatoid factor (RF): a key exclusion criterion that helps distinguish AOSD from rheumatoid arthritis and systemic lupus erythematosus.

A Specific Biomarker: Hyperferritinemia

• A sharply elevated serum ferritin (typically 5 to several dozen times the upper limit of normal, sometimes above 10,000 ng/mL).
• A markedly reduced glycosylated ferritin fraction (usually below 20%). Very high ferritin combined with a very low glycosylated fraction is a highly specific marker of adult-onset Still's disease.

How Adult-Onset Still's Disease Is Treated at Haute-Derma

Treatment of AOSD at Haute-Derma aims to break the acute innate inflammatory cascade, bring down the fever and protect the joints over the long term:

Acute-Phase Treatment (Stopping the Inflammatory Storm)

• High-dose systemic corticosteroids: our first-line mainstay at Haute-Derma for controlling severe systemic inflammation. Methylprednisolone or prednisolone is given at high doses by mouth or intravenously during the acute phase to rapidly suppress fever and serositis (pericarditis, pleuritis). Symptoms usually improve dramatically within a few days, after which the doctor tapers the dose very cautiously to avoid a relapse.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): considered as sole therapy only for mild cases with joint pain alone and no serious organ involvement. Potent agents such as indomethacin or naproxen are typically used.

Maintenance and Steroid-Sparing Therapy (csDMARDs)

To avoid the serious side effects of long-term corticosteroids (adrenal suppression, osteoporosis, diabetes), conventional immunomodulating drugs are added early:

• Methotrexate: the first-choice maintenance drug, especially effective for patients with a chronic joint-dominant pattern. It stabilizes the immune system and lets the doctor bring the corticosteroid dose down to a safe level sooner.
• Other csDMARDs: cyclosporine A, azathioprine or leflunomide may be used instead, depending on each patient's tolerance and specific organ involvement.

Next-Generation Targeted Biologic Therapy (bDMARDs): A Treatment Breakthrough

For AOSD that does not respond to corticosteroids and methotrexate, or that carries a risk of life-threatening complications, Haute-Derma uses targeted biologic therapies that act directly on the molecular disease mechanism:

• Interleukin-1 blockers (such as anakinra, canakinumab): regarded as the most transformative and best-targeted therapy for Still's disease. By blocking IL-1 signaling (the core cytokine of the NLRP3 inflammasome), they stop the fever almost at once, clear the rash and bring ferritin back to normal within just a few doses.
• Interleukin-6 blocker (tocilizumab): highly effective for both systemic features and chronic polyarthritis, thanks to its strong suppression of IL-6-driven inflammatory signaling.
• TNF-α blockers (such as adalimumab, infliximab): used mainly for late-stage disease dominated by persistent joint pain.